Skip Navigation



Rheumatology Advance Access published online on May 11, 2004
Rheumatology, doi:10.1093/rheumatology/keh222
Rheumatology © British Society for Rheumatology 2004; all rights reserved
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
43/8/969    most recent
keh222v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Corps, A. N.
Right arrow Articles by Riley, G. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Corps, A. N.
Right arrow Articles by Riley, G. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received January 30, 2004
Accepted April 8, 2004

Original Papers

Versican splice variant messenger RNA expression in normal human Achilles tendon and tendinopathies

A. N. Corps 1*, A. H. N. Robinson 2, T. Movin 3, M. L. Costa 2, D. C. Ireland 4, B. L. Hazleman 1, G. P. Riley 1

1 Rheumatology Research Unit , Addenbrooke's Hospital, Cambridge, UK
2 Department of Trauma and Orthopedics, Addenbrooke's Hospital, Cambridge, UK
3 Karolinska Institute, Centre for Surgical Studies, Department of Orthopedic Surgery, Karolinska University Hospital/Huddinge, Stockholm, Sweden
4 Bone Research Group, Department of Medicine, University of Cambridge, Cambridge, UK

* To whom correspondence should be addressed. E-mail: anc{at}mole.bio.cam.ac.uk.


  Abstract

Objectives. Versican is the principal large proteoglycan expressed in mid-tendon, but its role in tendon pathology is unknown. Our objective was to define the expression of versican isoform splice variant messenger ribonucleic acid (mRNA) in normal Achilles tendons, in chronic painful tendinopathy and in ruptured tendons.

Methods. Total RNA isolated from frozen tendon samples (normal n = 14; chronic painful tendinopathy n = 10; ruptured n = 8) was assayed by relative quantitative reverse transcriptase polymerase chain reaction (RT-PCR) for total versican, versican variants V0, V1, V2, V3 and type I collagen {alpha}1 mRNA, normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Differences between sample groups were tested by Wilcoxon statistics.

Results. Painful and ruptured tendons showed a significant decrease (median 2-fold) in the expression of versican mRNA, in contrast to an increased expression (median 8-fold) of type I collagen {alpha}1 mRNA in painful tendons. Versican splice variants V0 and V1 mRNA were readily detected in normal samples, V3 levels were substantially lower, and V2 levels were more variable. Each of V1, V2 and V3 mRNA showed significant decreases in expression in painful and ruptured tendons, but V0 was not significantly changed.

Conclusions. Changes in versican expression relative to that of collagen, and alterations in the balance of versican splice variants, may contribute to changes in matrix structure and function in tendinopathies.

KEY WORDS: Tendon, Tendinopathy, Versican, Proteoglycan.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
A. N. Corps, A. H. N. Robinson, T. Movin, M. L. Costa, B. L. Hazleman, and G. P. Riley
Increased expression of aggrecan and biglycan mRNA in Achilles tendinopathy
Rheumatology, March 1, 2006; 45(3): 291 - 294.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.